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Abstract
Background: New approaches and tools were needed to support the strategic planning, implementation and management
of a Program launched by the Brazilian Government to fund research, development and capacity building on neglected
tropical diseases with strong focus on the North, Northeast and Center-West regions of the country where these diseases
are prevalent.
Methodology/Principal Findings: Based on demographic, epidemiological and burden of disease data, seven diseases were
selected by the Ministry of Health as targets of the initiative. Publications on these diseases by Brazilian researchers were
retrieved from international databases, analyzed and processed with text-mining tools in order to standardize author- and
institution’s names and addresses. Co-authorship networks based on these publications were assembled, visualized and
analyzed with social network analysis software packages. Network visualization and analysis generated new information,
allowing better design and strategic planning of the Program, enabling decision makers to characterize network
components by area of work, identify institutions as well as authors playing major roles as central hubs or located at critical
network cut-points and readily detect authors or institutions participating in large international scientific collaborating
networks.
Conclusions/Significance: Traditional criteria used to monitor and evaluate research proposals or R&D Programs, such as
researchers’ productivity and impact factor of scientific publications, are of limited value when addressing research areas of
low productivity or involving institutions from endemic regions where human resources are limited. Network analysis was
found to generate new and valuable information relevant to the strategic planning, implementation and monitoring of the
Program. It afforded a more proactive role of the funding agencies in relation to public health and equity goals, to scientific
capacity building objectives and a more consistent engagement of institutions and authors from endemic regions based on
innovative criteria and parameters anchored on objective scientific data.
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Introduction
The World Health Organization (WHO) classifies diseases as
Type I, Type II and Type III, which largely corresponds to
Global, Neglected and Most Neglected diseases in the vocabulary
of the international organization Mede ´cins Sans Frontie `res (MSF)
[1,2]. Type I/Global diseases know no geographic boundaries
while Type II–III/Neglected-Most Neglected are predominantly
or exclusively prevalent among populations of developing
countries. Types II and III diseases (from now on ‘‘neglected
diseases’’), being prevalent in poor regions, are not prioritized by
pharmaceutical and biotechnological industries responsible for the
manufacture of goods such as vaccines, drugs and diagnostic kits.
This generates what is known as ‘market failures’ - the inefficient
allocation of products and services through usual free market
mechanisms.
Several procedures have been suggested to cope with the three
types of ‘‘health failures’’: (i) Science failures (insufficient knowledge
prevents the development of health products such as malaria and
HIV vaccines): Stimulate basic, fundamental research and
technological development, (ii) Market failures (high prices prevent
access of drugs by needy populations): Price reduction policies
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industry) or creating subsidizing mechanisms leading to lower
prices and (iii) Health service failures (inexpensive drugs do not reach
the patients): Fighting corruption, reducing inequalities and coping
with cultural, religious or infrastructure barriers, etc. that prevent
access to cheap or free drugs by poor countries [3,4].
Several initiatives have recently been proposed to stimulate
research, technological development and production of vaccines,
drugs and diagnostics for neglected diseases by both Big Pharma
and Small Biotech of developed countries such as ‘‘Push’’
mechanisms, like Public Private Partnerships (PPPs) or Partner-
ships for the Development of Products (PDPs), funded in general
by philanthropies or governments [5,6] and ‘‘Pull’’ mechanisms,
like Advance Market Commitments (AMCs), Orphan drug
legislation (e.g. the US Orphan Drug Act of 1983) and Priority
Review Vouchers issued under the Food and Drug Administration
Amendments Act of 2007 (FDAAA).
These mechanisms have in general been conceptualized and
implemented by the developed world and either international or
philanthropic organizations. They do not take full advantage of
the brainpower and infrastructure existing in middle-income
developing countries or in some innovative developing countries
(IDCs) [7] such as Brazil, where considerable progress has recently
been made in defining and implementing a national policy for
science, technology and innovation in health [8,9,10].
Research and development on neglected diseases is one of the key
strategic areas of Brazil’s priority agenda for health research [8,11].
In 2005 the MinistryofHealthtogetherwith theMinistry ofScience
and Technology, through their funding agencies DECIT (Depart-
ment of Science and Technology, http://dtr2001.saude.gov.br/
sctie/decit/index.htm) and CNPq (National Council for Scientific
and Technological Development, http://www.cnpq.br/english/
cnpq/index.htm), launched a joint Program to support research,
technological development and innovation on six diseases that
disproportionately hit poor and marginalized populations in Brazil:
dengue, Chagas disease, leishmaniases, leprosy, malaria and
tuberculosis. In 2008 schistosomiasis was added to the list and a
2nd call for applications instituted (http://www.cnpq.br/editais/
ct/2008/034.htm). For additional detais on this DECIT/CNPq
Program see Serruya et al [11,12].
As equity and capacity building were considered critical
components of the Program, it was decided to invest at least
30% of the financial resources in the three Brazilian geographic
Regions where these diseases are still prevalent (North, Northeast
and Center-West). Since the scientific productivity related to
neglected diseases is less than in other areas of health sciences and
several institutions located in these Regions are still maturing,
traditional indicators such as number of scientific articles and
impact factor of the journals where they were published would be
of only limited value. We therefore decided to develop new
approaches and criteria based on social network analysis
[13,14,15,16], to allow for a fair and efficacious allocation of
resources without losing sight of scientific standards.
Methods
Data mining
Publications by Brazilian authors on the seven diseases were
retrieved as raw data files from the ‘Web of Knowledge’ database
of the Institute for Scientific Information (ISI), a database that lists
the full addresses of all authors of every paper. Queries were made
in ‘advanced search’ mode directed simultaneously at the country
name and at words in the titles of the papers, e.g. [CU=Brazil
AND TI=(Chagas OR cruzi)] to retrieve papers with at least one
researcher from Brazil among the authors and having ‘‘Chagas
disease’’ or ‘‘Trypanosoma cruzi’’ in the title.
Standardization of names and addresses of authors and
institutions
The ISI raw data files were imported into the text-mining
software VantagePoint (http://www.thevantagepoint.com) with
the appropriate ISI filters. A process of standardization was carried
out to bring together the various different names of a particular
author or institution [17] and VantagePoint thesauri for names
and addresses were created in order to process additional name
and address lists.
Network assembly, visualization and analysis
Co-occurrence matrices of authorship data were built into
VantagePoint and exported to UCINET software for social
network analysis [18]. A co-occurrence matrix shows the number
of records in the dataset containing two given list items.
Symmetrical, co-occurence matrices (also called ‘adjacency
matrices’) were created using the same set of authorship data in
rows and columns in order to map co-authorships between authors
(authors6authors matrices) or institutions (institutions6institutions
matrices). For additional details on the use of matrices in social
network analysis see for instance Chapter 3 of Scott [19],
‘‘Handling Relational Data’’. Networks were assembled, visualized
and analyzed for several parameters such as network components
and cut-points with the softwares NetDraw or Pajek [20] which
are embedded in the UCINET package.
Results
Publications on seven neglected diseases by Brazilian
authors in peer-reviewed international journals
The scientific environment where the Program is based and
operates can be assessed analyzing the scientific productivity of
Brazilian authors and institutions in peer-reviewed international
journals. Table 1 and Figure 1 display that it varies widely among
Author Summary
The selection and prioritization of research proposals is
always a challenge, particularly when addressing neglect-
ed tropical diseases, as the scientific communities are
relatively small, funding is usually limited and the disparity
between the science and technology capacity of different
countries and regions is enormous. When the Ministry of
Health and the Ministry of Science and Technology of
Brazil decided to launch an R&D program on neglected
diseases for which at least 30% of the Program’s resources
were supposed to be invested in institutions and authors
from the poorest regions of Brazil, it became clear to us
that new strategies and approaches would be required.
Social network analysis of co-authorship networks is one of
the new approaches we are exploring to develop new
tools to help policy-/decision-makers and academia jointly
plan, implement, monitor and evaluate investments in this
area. Publications retrieved from international databases
provide the starting material. After standardization of
names and addresses of authors and institutions with text
mining tools, networks are assembled and visualized using
social network analysis software. This study enabled the
development of innovative criteria and parameters,
allowing better strategic planning, smooth implementa-
tion and strong support and endorsement of the Program
by key stakeholders.
Co-authorship Networks
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greater for Chagas disease and leishmaniases as compared with
dengue and leprosy.
Visualization and analysis of co-authorship networks
Co-authorship network analyses were carried out at several
stages of the two phases of the Programme: Phase I included six
diseases, funding projects during the biennium 2007–2008 and the
ongoing Phase II addresses seven diseases during the 2009–2010
biennium. We decided to focus our attention on network
components and network cut-points, basic elements of social
network analysis [19,21] that generate visual information readily
useful for Program managers and decision-makers. In this way we
emphasized the generation of graphical displays over a purely
quantitative, numerical analysis.
Components
A component of a network is a portion of the network in which
all actors are connected, directly or indirectly, by at least one tie
(one co-authorship in the present work) [21]. Fig. 2 shows the
component analysis of the 2001–2008 dengue co-authorship
network, where 172 authors are distributed among 9 components,
each one addressing in isolation its own set of specific,
complementary or overlapping research topics and subjects.
Cut-points
A cut-point of a network is an actor (author or institution in our
case) whose removal would increase the number of components by
dividing the sub-graph into two or more separate subsets between
which there are no connections. Cut-points are therefore pivotal
points of articulation between the elements that make up a
component [19]. The role of cut-points is exemplified in Fig. 3,
which shows the 2006–2007 tuberculosis institutional co-author-
ship network with the cut-point nodes labeled and identified as red
squares. In this network, for instance, the removal of the cut-point
‘‘Inst. Trop. Med. Prince Leopold’’ would disconnect FURG and
IVIC from the network and the removal of the cut-point
‘‘UNICAMP’’ would do the same for the University of Illinois.
The visualization of this network also demonstrates the power of
Table 1. Publications by disease and year by Brazilian authors
for the 2001–2008 period.
Year Dengue Leprosy Malaria TB Schisto Leish Chagas Total
2 0 0 1 1 0 2 4 3 62 3 5 47 5 9 33 1 5
2002 10 17 28 26 72 97 103 353
2003 16 22 30 36 42 89 135 370
2004 15 23 35 42 66 87 125 393
2005 20 23 42 52 57 120 144 458
2006 26 21 50 59 100 136 157 549
2007 43 45 64 67 52 171 165 607
2008 68 62 83 141 61 214 236 865
Totals 208 237 368 446 504 989 1158 3910
The following words or combination of words were used to retrieve
publications from Thomson Reuters’ ISI Web of Knowledge database by
querying the titles of the articles: dengue; leprosy OR leprae; malaria* OR vivax
OR falciparum; tuberculosis; schistosom* OR mansoni; leishm* OR antileishm*;
Chagas OR cruzi.
doi:10.1371/journal.pntd.0000501.t001
Figure 1. Evolution of publications by Brazilian authors on the seven neglected diseases covered by the DECIT/CNPq Program.
Publications were retrieved from Thomson Reuters’ ISI Web of Knowledge using the queries described in Methods. The recent increase in the
scientific productivity occurs in all diseases with the exception of schistosomiasis, which was not included in phase I of the Program.
doi:10.1371/journal.pntd.0000501.g001
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of a given network. In this figure, the large agglomerate of nodes at
the upper left immediately stands out, drawing one’s attention to
the presence of a publication involving a large number of
coauthors and their institutions, an indicator of projects involving
global networks.
Discussion
Evaluation of scientific productivity on neglected
diseases: the need for new strategies and approaches
Traditional scientific production indicators routinely adopted as
criteria for evaluating scientific proposals and research funding
programs, such as the number of publications in a given period of
time and impact factor or H-index [22], have intrinsic shortcom-
ings [23,24] and are of limited value beyond ‘Mode 1’ of
knowledge production (disciplinary, primarily cognitive, context)
[25] or when the publication output of the work field or the
scientific community under consideration is of small size. In fact a
‘Catch-22’ type challenge (a no-win situation or a double bind
dilemma, see http://en.wikipedia.org/wiki/Catch-22) arises when
considering these indicators to select candidates eligible for
capacity building purposes, as the researchers and institutions
most in need of support are exactly those who have a modest
scientific curriculum or performance. Traditional evaluations
therefore become a real barrier to career progress or towards
institutional development.
The management of the DECIT/CNPq Program, having
received the double mandate to adhere to high scientific standards
andstrengthen capacityinthe less developed Regions of the country,
as two pillars of the initiative, realized that new strategies and
indicators would be needed. The 2001–2008 survey of publications
shown in Tables 1 and 2 well illustrates some of the challenges the
Programwouldface,forinstance:(i)threeoutofthefourmostactive
research communities (Chagas disease, schistosomiasis and tuber-
culosis) are located in the developed South and Southeast of Brazil,
far from the target Regions for capacity building and (ii) dengue, a
disease that has caused serious problems for public health in recent
Figure 2. Components, dengue co-authorship researchers network, 2001–2008. Each square represents one author and each line
connecting two authors indicates the presence of at least one publication they have co-authored. Components are defined by the observed co-
authorships for the period under analysis; authors in one component have no publication in collaboration with authors of other components. This
dengue network includes 174 authors with 2 or more papers published during the 2001–08 time span and contains nine components (labeled I–IX).
The areas of work of the minor components can be inferred from the analysis of the most frequent keywords listed in their publications:
Component II: blood donors; Brasil; dengue virus nucleic acid test; dengue virus RNA; detection; development; high-throughput blood screening;
Honduras; prototype transcription-mediated amplification assay. Component III: social representations; control activities; dengue vectors; plant
vases; relationships; residents; Sao Paulo State. Component IV: classical dengue fever; dengue shock syndrome; liver transplant recipient; liver
transplantation. Component V: antiviral activity; algal-derived DL-galactan hybrid; carrageenans; chemical structure; Meristiella gelidium; sulfated
polysaccharides; virus serotype; vitro dengue virus infection. Component VI: high dosages; dengue hemorrhagic fever; gamma globulin;
immunoglobulin; serious thrombocytopenia; treatment. Component VII: apoptosis; dengue virus fusion peptide; dengue virus infection; energy
charge; HepG2 cell; lipid membrane; membrane fusion; metabolism; mitochondrial dysfunction; oligomerization; partition. Component VIII: Aedes
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communities and needs ‘fast-track’ capacity building actions.
Two social network analysis tools proved to generate particu-
larly valuable information for the strategic management of the
Program, the identification of components and cut-points of the
co-authorship networks:
Identification and characterization of network
components
Component analysis generates a picture of the overall network
structure, revealing how fragmented it is and therefore providing
valuable information on its status and opportunities for strategic
management. As shown in Fig. 2 for the dengue researcher’s
network, the analysis of the work areas of the nine individual
components, based on article keywords, suggested for instance, a
collaboration between component III and VIII, as their research-
ers were all working on dengue vector control but did not engage
in formal collaborations.
Identification and characterization of network cut-points
The identification of network cut-points became a very
important analytical tool for the management of the Program,
particularly in relation to its capacity building/strengthening
mandate. As the majority of institutions in the less developed
Regions still need to mature, a selection based exclusively on
scientific productivity would place them at a clear disadvantage in
comparison with sister institutions from the developed Southeast
and South. We realized that institutions acting as network cut-
points were critical key players as they were responsible for
keeping several institutions from these Regions in the loop and
should therefore be considered as fundamental partners for
training, capacity building and institutional strengthening. This
reasoning is supported by work in other fields that made evident
the importance of scientists who play roles as brokers for
communications among others [14], the function of nodes
critically involved in connecting or bridging modular subregions
of a network [26] or the cruciality of ‘creative elements’ in cells,
social networks and ecosystems [27].
Table 2 shows that by adopting this cut-point criterion to help
the selection of institutions worth strengthening, nine ‘cut-point
institutions’ could be added to the eleven ‘top-10 institutions’
identified by classical high-productivity criteria. The Program
could therefore double the number of potential investment targets
in the North, Northeast and Center-West Regions with objective
science-based parameters: the traditional, productivity-based
Figure 3. Cut-points, tuberculosis co-authorship institutions network, 2006–2007. Each node represents an institution that published at
least one article in the biennium 2006–07. Nodes in red are institutions that function as cut-points in this network: the Oswaldo Cruz Institute at the
Oswaldo Cruz Foundation (Fiocruz/IOC) in Rio de Janeiro; the Prince Leopold Institute of Tropical Medicine or Institute of Tropical Medicine (ITM) in
Antwerp; the Federal University of Espı ´rito Santo (UFES); the Federal University of Minas Gerais (UFMG); the Federal University of Rio de Janeiro (UFRJ);
the University of Campinas (UNICAMP); the University of Sa ˜o Paulo in Ribeira ˜o Preto (USP/Ribeira ˜o Preto); and the University of Sa ˜o Paulo in Sa ˜o Paulo
(USP/Sa ˜o Paulo). The role of ITM as a cut-point derives from the article by da Silva et al, co-authored by seven authors from ITM, the Federal University
of Rio Grande, RS, Brazil (FURG) and the Instituto Venezolando de Investigaciones Cientificas, Caracas, Venezuela (IVIC) [36]; in a similar way the paper
by Pasqualoto et al links the University of Illinois to the TB network through the cut-point UNICAMP [37]. The large agglomerate of nodes is due to
the article by Brudey et al [38] which has 66 authors from 42 institutions, two of them acting as cut-points (Fiocruz/IOC and ITM).
doi:10.1371/journal.pntd.0000501.g003
Co-authorship Networks
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analysis proposed in this article.
How were the new approach and indicators put into
action?
The Program was shaped to operate in ‘Mode 2’ of knowledge
production (broader, transdisciplinary social and economic con-
texts) [25] as its mission goes beyond academic goals to also address
capacity building, institution strengthening, product development,
disease control and public health. In Brazil’s national health system
(SUS - Sistema U ´nico de Sau ´de) the participation of civil society and
communities is assured at all levels of government - federal, state
and municipal [28]. The process leading to the prioritization of
R&D on neglected diseases, which made possible the launching of
the DECIT/CNPq Program and set its main objectives and goals,
involved strong participation of these key stakeholders e.g. at the
National Health Council (http://conselho.saude.gov.br/apresenta-
cao/index.htm) and at the 2nd National Conference on Science,
Technology, and Innovation in Health held in 2004 which involved
15,000 participants [8].
Mobilizing the scientific community, disease control managers
and policy/decison-makers to collaborate under the umbrella of this
initiative required a sort of ‘cultural change’ from everyone involved.
For this purpose the process adopted by the Program included: (i)
Organizing priority setting workshops with equal representation by
researchers, policy/decision-makers and managers interested in the
seven diseases of the Program; (ii) Adopting guiding principles such
as burden of disease and classical/network-based science indicators
as the basis for workshop agendas and discussions; (iii) Structuring
these workshops on disease-specific working groups with equal
representation of policy/decision-makers, managers and scientists of
high productivity and/or affiliated to network cut-point institutions;
(iv) Mobilizing the participation of scientific communities through
‘CallforApplications’basedonthe recommendationsoftheworking
groups and published inthe websitesof the funding agencies;(v) Peer
reviewing of the proposals taking into account the need to allocate a
minimum of 30% of the funds to projects submitted by principal
investigators affiliated to institutions in the North, Northeast and
Center-West Regions.
Fig. 1 suggests that the DECIT/CNPq Program has been
successful in stimulating scientific productivity on the six diseases
in its first phase which did not include schistosomiasis as one of the
targets. The future assessment of the full impact of the two phases,
however, will need a thorough in-depth evaluation exercise based
on input, output, outcome and impact indicators addressing
scientific, technological and public health goals. Co-authorship
network analysis has been employed to evaluate scientific journals
[29,30], institutions [31] and collaboration patterns in specific
scientific fields [17]. The innovative contribution brought by this
analytical approach during the shaping and implementation of the
Program will be expanded and become critical when assessing the
evolution, performance and robustness of the networks involved.
Ourresultsalso suggest thatco-authorship networkanalysis could
become an important tool for international organizations or
partnerships targeting the elimination or eradication of diseases,
providing science-based information relevant to strategic analysis
and planning. Lessons from past eradication campaigns demon-
strated the importance of maximizing the utilization of scarce
human and financial resources, functioning within existing health
service structures and encouraging research at all levels [32].
Applied to today’s planned efforts towards the elimination/
eradication of malaria [33,34] or neglected tropical diseases [35],
these lessons would mean identifying and engaging health services,
researchers and institutions from developed and endemic countries,
an immense challenge that co-authorship network analysis could
help address, providing a substantial contribution to global health.
Supporting Information
Alternative Language Abstract S1 Spanish translation of the
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Table 2. Geographic distribution of key network institutions conducting R&D on the neglected diseases of the DECIT/CNPq
Program, 2001–2007.
Disease Top-109 institutions by number of publications
Additional N/NE/CW institutions identified by
their cut-point location in co-authorship networks
N/NE/CW S/SE Foreign
Chagas disease 0 10 0 Hospital Anis Rassi; UFPE
Dengue 4 6 0 CEPEM
Leishmaniases 2 8 0 UFGO; UFRN
Leprosy 1 7 2* UFCE
Malaria 4 6 0 CEPEM; UFBA
Schistosomiasis 0 7 3** CCBi; CPqAM; UFBA
Tuberculosis 0 10 0 None
Total 11 54 5 The above 9 additional institutions were identified by the cut-point criterion
70
For each disease we mapped the ten institutions ranking higher in total number of publications on neglected diseases in international peer-reviewed journals having at
least one Brazilian author (the ‘top-10’ institutions in Chagas, the ‘top-10’ in dengue, etc.). The majority of the ‘top-10’ Brazilian institutions are located in the more
developed regions of Brazil (South/Southeast, 54 institutions) and not where most of these diseases are endemic (North/Northeast/Center-West, 11 institutions). Co-
authorship network analysis allowed the identification of 9 additional key institutions from these less developed regions based on another criterion: their critical role in
contributing to network structure, function and sustainability due to their location at ‘cut-points’ of the networks. Brazilian cut-point institutions at N/NE/CW: Aggeu
Magalha ˜es Research Center (CPqAM), Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco; Center for the Biological Sciences, Federal University of Alagoas, Maceio ´,
Alagoas (CCBi); Federal University of Bahia (UFBA); Federal University of Ceara ´ (UFCE); Federal University of Goia ´s (UFGO); Federal University of Pernambuco (UFPE);
Federal University of Rio Grande do Norte (UFRN); Hospital Anis Rassi, Goiania, Goia ´s; Tropical Medicine Research Center, Porto Velho, Rondonia (CEPEM).
Foreign institutions collaborating with Brazilian authors: * London School of Hygiene and Tropical Medicine; University of Tubingen; ** University of Glasgow; Purdue
University; George Washington University.
doi:10.1371/journal.pntd.0000501.t002
Co-authorship Networks
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